Electrophysiology of esmolol
- PMID: 2864844
- DOI: 10.1016/0002-9149(85)90912-9
Electrophysiology of esmolol
Abstract
The electrophysiologic characteristics of esmolol were studied in 14 patients. Ten men and 4 women, mean age 57 years, were electrophysiologically evaluated at baseline, and also at 4 to 8 minutes after the administration of a maintenance infusion of esmolol. Plasma samples for esmolol blood levels were drawn at 10 minutes of the maintenance infusion, at the end of the maintenance infusion and 30 minutes after the maintenance infusion was discontinued. Results of this study showed that esmolol has typical beta-blocker electrophysiologic effects. Its major action was on sinus node function; it prolonged this basic sinus cycle length but had no significant effect on intrinsic automaticity as reflected by the corrected sinus node recovery time and sinoatrial conduction. Direct effects on atrioventricular (AV) nodal function were reflected by effects on AV nodal conduction and refractoriness. There was no direct effect on atrial function and, as expected, no effect on His-Purkinje or ventricular function. The intensity of esmolol's electrophysiologic effects on sinus node function, AV nodal conduction and AH interval is comparable to those of other beta blockers.
Similar articles
-
The electrophysiologic properties of esmolol, a short acting beta-blocker.Int J Clin Pharmacol Ther Toxicol. 1988 Apr;26(4):209-16. Int J Clin Pharmacol Ther Toxicol. 1988. PMID: 2900217
-
Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker.Am Heart J. 1986 Jan;111(1):49-53. doi: 10.1016/0002-8703(86)90552-1. Am Heart J. 1986. PMID: 2868646
-
Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.Cardiology. 2002;97(3):138-46. doi: 10.1159/000063330. Cardiology. 2002. PMID: 12077566
-
The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction.J Clin Pharmacol. 1988 Jan;28(1):6-21. doi: 10.1002/j.1552-4604.1988.tb03095.x. J Clin Pharmacol. 1988. PMID: 2450898 Review.
-
Basic pharmacology of esmolol.Am J Cardiol. 1985 Oct 23;56(11):3F-13F. doi: 10.1016/0002-9149(85)90910-5. Am J Cardiol. 1985. PMID: 2864846 Review.
Cited by
-
Drug effects on the sinus node. A clinical perspective.Cardiovasc Drugs Ther. 1988 Jul;2(2):165-70. doi: 10.1007/BF00051231. Cardiovasc Drugs Ther. 1988. PMID: 3154702 Review.
-
Noninvasive Assessment of Atrioventricular Nodal Function: Effect of Rate-Control Drugs during Atrial Fibrillation.Ann Noninvasive Electrocardiol. 2015 Nov;20(6):534-41. doi: 10.1111/anec.12253. Epub 2014 Dec 26. Ann Noninvasive Electrocardiol. 2015. PMID: 25545540 Free PMC article. Clinical Trial.
-
Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.Eur J Clin Pharmacol. 1994;46(5):399-404. doi: 10.1007/BF00191900. Eur J Clin Pharmacol. 1994. PMID: 7957532 Clinical Trial.
-
Modification of the haemodynamic responses to induction of anaesthesia and tracheal intubation with alfentanil, esmolol and their combination.Can J Anaesth. 1995 Apr;42(4):298-304. doi: 10.1007/BF03010706. Can J Anaesth. 1995. PMID: 7788827 Clinical Trial.
-
Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.Clin Cardiol. 1998 Jul;21(7):492-502. doi: 10.1002/clc.4960210708. Clin Cardiol. 1998. PMID: 9669058 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources